NASH Highlights


18 August 2017

Organ crosstalk: Fatty liver can cause damage to other organs

“According to the article, fatty liver increases the risk of chronic liver diseases (liver cirrhosis and liver cancer), as well as type 2 diabetes and cardiovascular diseases. How this happens is that the fatty liver increasingly produces glucose, unfavorable fats and proteins, such as the hepatokine fetuin-A, all of which it releases into the bloodstream and enters other organs, triggering adverse reactions.”

26 July 2017

NASH linked to early markers of hypertrophy

“Whether diastolic dysfunction similarly portends a risk of future [heart failure] among patients with NAFLD and/or NASH remains unknown, and we eagerly await well-designed, prospective studies to characterize this relationship.”

19 July 2017

AASLD releases NAFLD practice guides for screening, treatment

“There is a paucity of data regarding the incidence of NAFLD in the general population. ... The incidence rates for NAFLD in the general population of Western countries are even less commonly reported [than those in Asian countries],” the researchers wrote.

“In contrast to the incidence data, there is a significantly higher number of publications describing the prevalence of NAFLD in the general population.”


6 July 2017


Millions of people are living with a silent disease they've likely never heard of

... And NASH is set to surpass hepatitis as the biggest reason for liver transplants by 2020. That is seriously alarming!


5 July 2017


NASH: KOL Insight

Key takeaway from experts on current study designs and endpoints, and the challenges facing novel therapies such as long-term safety, cost and diagnosis.


3 July 2017


Fatty liver disease can be a silent killer

According to a report in Singapore's The New Paper (TNP), Non-alcoholic fatty liver disease - which can lead to liver cirrhosis or cancer - is on the rise in Singapore.


30 June 2017


AASLD Foundation announces $3.34 Million in liver disease research and career development funding

“Liver disease continues to be a critical healthcare issue in the United States and internationally. Despite recent strides and successes in the treatment of many liver diseases, AASLD Foundation understands there is still much work to be done and more funding must be made available to those interested in hepatology.” - Bruce R. Bacon, MD, FAASLD, AASLD Foundation Chair.

26 June 2017

Looking for clues for dangerous fatty liver disease

"When you combine the fact that the natural history of the disease is unclear; it's difficulty to diagnose, treat and stage it; and there's no FDA-approved medicine, it becomes a huge issue." - Dr. Jaideep Behari, associate professor of medicine at the University of Pittsburgh and director of Fatty Liver Clinic.

Click on the headline to read the article on fatty liver disease and nonalcoholic steatohepatitis (NASH).

Story by Medical Xpress


19 June 2017

First-degree relatives of patients with NAFLD-cirrhosis at risk for advanced fibrosis

"According to researchers, first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis have a 12-times higher risk for developing advanced fibrosis compared with first-degree relatives without NAFLD."

Story by Healio


13 June 2017

Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027

Report by Research and Markets.


6 June 2017

New study indicates that drinking even a few cups a day may prevent hardening of the liver, reports the Journal of Hepatology. So don't forget that cuppa, everyone!



1 June 2017

EMA consults on regulatory requirements for chronic liver disease drugs

“Specifically, EMA says the diseases pose a significant challenge for drugmakers to study, as all three have a long progression and symptoms that are either unspecific or non-predictive of long-term outcomes. Furthermore, EMA says the use of "hard" clinical outcomes like liver transplantation or death raise feasibility issues for studies, and the need for repeated liver biopsies deters patients from enrolling in studies and increases risk.

Because of these challenges, EMA says there is a strong need for a validated surrogate endpoint to reduce the need for biopsies.”

Story by Regulatory Affairs Professional Society


31 May 2017

Commissioner Carlos Moedas on the importance of research and innovation in fighting NAFLD and NASH

During the first European- NAFLD-NASH Policy Summit last month, Carlos Moedas, European Commissioner for Research, Science and Innovation, stressed the "need to scale up efforts in research and innovation [to] develop simple, cost-effective and non-invasive tests" that will allow to "improve guidance to member states on primary care and better management".

Read more and watch this video to hear the full message.

Story by the European Liver Patients Association (ELPA)

Note: Organised by the ELPA, the first European- NAFLD-NASH Policy Summit took place on May 31 this year. The event addressed potential measures to reduce the burden of NAFLD/NASH.